We are live on
!
Find out more
LCM
Laurion Capital Management Portfolio holdings
AUM
$2.29B
1-Year Est. Return
75.73%
This Fund
S&P 500
This Quarter
Est. Return
+6.97%
1 Year Est. Return
+75.73%
3 Year Est. Return
+162.63%
5 Year Est. Return
+130.38%
10 Year Est. Return
+388.8%
AUM
$17.9B
AUM Growth
+$3.18B
(+22%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.82%
Top 10 Holdings %
Top 10 Hldgs %
38.29%
Holding
721
New
293
Increased
98
Reduced
124
Closed
140
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$124M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$95.2M |
| 3 |
Pliant Therapeutics
PLRX
|
+$74.8M |
| 4 |
Microsoft
MSFT
|
+$72.6M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$56.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$123M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$60.4M |
| 3 |
Emerson Electric
EMR
|
+$55M |
| 4 |
Home Depot
HD
|
+$54.8M |
| 5 |
Comcast
CMCSA
|
+$53.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 5.44% |
| 2 | Technology | 2.51% |
| 3 | Communication Services | 1.69% |
| 4 | Utilities | 1.38% |
| 5 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCM
426
DELISTED
R1 RCM Inc. Common Stock
RCM
| $449K | ﹤0.01% |
+24,342
| New | +$395K |
|
|
LNW
427
DELISTED
Light & Wonder
LNW
| $444K | ﹤0.01% |
+6,451
| New | +$401K |
|
|
APLT
428
DELISTED
Applied Therapeutics
APLT
| $443K | ﹤0.01% |
345,900
| – | – |
|
429
Dianthus Therapeutics
DNTH
$6.09B
| $441K | ﹤0.01% |
36,394
| – | – |
|
|
BCEL
430
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $421K | ﹤0.01% |
429,176
-63,024
| -13% | -$64.9K |
|
431
Cognex
CGNX
$11.3B
| $408K | ﹤0.01% |
+7,291
| New | +$377K |
|
432
Copa Holdings
CPA
$5.8B
| $407K | ﹤0.01% |
+3,680
| New | +$369K |
|
433
Wells Fargo
WFC
$264B
| $399K | ﹤0.01% |
9,350
-122,506
| -93% | -$4.93M |
|
434
Clearway Energy Class C
CWEN
$6.7B
| $394K | ﹤0.01% |
+13,799
| New | +$417K |
|
435
Privia Health
PRVA
$2.87B
| $382K | ﹤0.01% |
+14,623
| New | +$386K |
|
436
Xilio Therapeutics
XLO
$60.3M
| $374K | ﹤0.01% |
10,207
| – | – |
|
437
Vail Resorts
MTN
$5.3B
| $374K | ﹤0.01% |
+1,484
| New | +$362K |
|
|
VALN
438
Valneva
VALN
$541M
| $367K | ﹤0.01% |
25,000
| – | – |
|
|
LSXMA
439
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
| $367K | ﹤0.01% |
+15,208
| New | +$324K |
|
440
Arista Networks
ANET
$238B
| $366K | ﹤0.01% |
+9,036
| New | +$349K |
|
441
Archer Daniels Midland
ADM
$36.9B
| $359K | ﹤0.01% |
+4,747
| New | +$359K |
|
|
API
442
Agora
API
$377M
| $352K | ﹤0.01% |
112,436
-54,862
| -33% | -$178K |
|
443
iShares Silver Trust
SLV
$30.9B
| $334K | ﹤0.01% |
16,000
-100
| -0.6% | -$2.22K |
|
444
Iron Mountain
IRM
$36.1B
| $330K | ﹤0.01% |
+5,800
| New | +$318K |
|
445
General Motors
GM
$76.8B
| $328K | ﹤0.01% |
8,500
+4,924
| +138% | +$170K |
|
446
Mustang Bio
MBIO
$4.55M
| $317K | ﹤0.01% |
1,020
-907
| -47% | -$228K |
|
|
CTV
447
DELISTED
Innovid Corp.
CTV
| $316K | ﹤0.01% |
290,305
| – | – |
|
448
MaxLinear
MXL
$6.8B
| $316K | ﹤0.01% |
10,000
| – | – |
|
449
Tootsie Roll Industries
TR
$2.98B
| $310K | ﹤0.01% |
+9,580
| New | +$350K |
|
450
Robert Half
RHI
$4.37B
| $308K | ﹤0.01% |
+4,101
| New | +$293K |
|
Similar funds
AFM
GCP
LCM
MAP
MA
LFM
NSAM
ABI
Laurion Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Laurion Capital Management held 721 positions worth $17.9B, up 22% from $14.7B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Laurion Capital Management deployed $2.11B of net new capital in Q2 2023, opening 293 new positions and adding to 98 existing holdings. Its largest new stake was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
By sector, the portfolio is most concentrated in Healthcare at 5.4% of assets, down from 6.6% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Viatris, an estimated $123M trimmed.
- Laurion Capital Management's largest Q2 2023 buy was Pliant Therapeutics: 3,158,570 shares worth $57.2M.
- Laurion Capital Management added most to T-Mobile US in Q2 2023, an estimated $124M increase.
- Laurion Capital Management's biggest Q2 2023 reduction was Viatris, cutting an estimated $123M.
- Laurion Capital Management fully exited CATALENT, INC. in Q2 2023, selling an estimated $60.4M.
- Laurion Capital Management's ten largest holdings make up 38% of its $17.9B portfolio in Q2 2023.
- Laurion Capital Management opened 293 new positions and closed 140 in Q2 2023.
- Laurion Capital Management's portfolio value rose 22% quarter-over-quarter to $17.9B.
Based on Laurion Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.